188 related articles for article (PubMed ID: 28052121)
21. A Single Nucleotide Polymorphism (SNP) in the
Li J; Persaud AK; Johnson JA; Sborov DW; Phelps MA; Hofmeister CC; Poi MJ
Anticancer Res; 2022 Jan; 42(1):385-395. PubMed ID: 34969749
[TBL] [Abstract][Full Text] [Related]
22. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
Spencer A; Horvath N; Gibson J; Prince HM; Herrmann R; Bashford J; Joske D; Grigg A; McKendrick J; Prosser I; Lowenthal R; Deveridge S; Taylor K;
Bone Marrow Transplant; 2005 May; 35(10):971-7. PubMed ID: 15778725
[TBL] [Abstract][Full Text] [Related]
23. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.
Thieblemont C; Dumontet C; Saad H; Roch N; Bouafia F; Arnaud P; Hequet O; Espinouse D; Salles G; Roy P; Eljaafari-Corbin A; Du Manoir-Baumgarten C; Coiffier B
Bone Marrow Transplant; 2002 Dec; 30(11):769-75. PubMed ID: 12439700
[TBL] [Abstract][Full Text] [Related]
24. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients.
Aisa Y; Mori T; Kudo M; Yashima T; Kondo S; Yokoyama A; Ikeda Y; Okamoto S
Support Care Cancer; 2005 Apr; 13(4):266-9. PubMed ID: 15668755
[TBL] [Abstract][Full Text] [Related]
25. Early salivary changes in multiple myeloma patients undergoing autologous HSCT.
van Leeuwen S; Proctor GB; Potting C; Ten Hoopen S; van Groningen L; Bronkhorst EM; Blijlevens N; Huysmans M
Oral Dis; 2018 Sep; 24(6):972-982. PubMed ID: 29637662
[TBL] [Abstract][Full Text] [Related]
26. A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients.
Jantunen E; Kuittinen T; Nousiainen T
Leuk Lymphoma; 2002 Oct; 43(10):1961-5. PubMed ID: 12481892
[TBL] [Abstract][Full Text] [Related]
27. Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study.
Lalla RV; Pilbeam CC; Walsh SJ; Sonis ST; Keefe DM; Peterson DE
Support Care Cancer; 2010 Jan; 18(1):95-103. PubMed ID: 19404685
[TBL] [Abstract][Full Text] [Related]
28. Factors influencing the incidence and severity of oral mucositis in patients undergoing autologous stem cell transplantation.
Salvador PT
Can Oncol Nurs J; 2005; 15(1):29-34. PubMed ID: 15779780
[TBL] [Abstract][Full Text] [Related]
29. [Cryotherapy is useful and safe in the prevention of oral mucositis after high-dose melphalan (L-PAM)].
Inagaki N; Ohue Y; Shigeta H; Tasaka T
Rinsho Ketsueki; 2006 Nov; 47(11):1469-71. PubMed ID: 17176891
[TBL] [Abstract][Full Text] [Related]
30. Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study.
Marchesi F; Tendas A; Giannarelli D; Viggiani C; Gumenyuk S; Renzi D; Franceschini L; Caffarella G; Rizzo M; Palombi F; Pisani F; Romano A; Spadea A; Papa E; Canfora M; Pignatelli A; Cantonetti M; Arcese W; Mengarelli A
Bone Marrow Transplant; 2017 Jan; 52(1):154-156. PubMed ID: 27526285
[No Abstract] [Full Text] [Related]
31. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
[TBL] [Abstract][Full Text] [Related]
32. Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan.
Tamaki M; Nakasone H; Gomyo A; Hayakawa J; Akahoshi Y; Harada N; Kusuda M; Ishihara Y; Kawamura K; Tanihara A; Sato M; Terasako-Saito K; Kameda K; Wada H; Kikuchi M; Kimura SI; Kako S; Kanda Y
Int J Hematol; 2018 Oct; 108(4):423-431. PubMed ID: 30039440
[TBL] [Abstract][Full Text] [Related]
33. Oral integrity and salivary profile in myeloma patients undergoing high-dose therapy followed by autologous SCT.
Avivi I; Avraham S; Koren-Michowitz M; Zuckerman T; Aviv A; Ofran Y; Benyamini N; Nagler A; Rowe JM; Nagler RM
Bone Marrow Transplant; 2009 May; 43(10):801-6. PubMed ID: 19029961
[TBL] [Abstract][Full Text] [Related]
34. Microarray analyses of oral punch biopsies from acute myeloid leukemia (AML) patients treated with chemotherapy.
Mougeot JL; Bahrani-Mougeot FK; Lockhart PB; Brennan MT
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Oct; 112(4):446-52. PubMed ID: 21862359
[TBL] [Abstract][Full Text] [Related]
35. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
36. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
37. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.
Blijlevens N; de Château M; Krivan G; Rabitsch W; Szomor A; Pytlik R; Lissmats A; Johnsen HE; de Witte T; Einsele H; Ruutu T; Niederwieser D;
Bone Marrow Transplant; 2013 Jul; 48(7):966-71. PubMed ID: 23241739
[TBL] [Abstract][Full Text] [Related]
38. Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
Waśko-Grabowska A; Rzepecki P; Oborska S; Barzał J; Gawroński K; Młot B; Szczylik C
Transplant Proc; 2011 Oct; 43(8):3111-3. PubMed ID: 21996239
[TBL] [Abstract][Full Text] [Related]
39. Oral mucositis-related oropharyngeal pain and correlative tumor necrosis factor-alpha expression in adult oncology patients undergoing hematopoietic stem cell transplantation.
Fall-Dickson JM; Ramsay ES; Castro K; Woltz P; Sportés C
Clin Ther; 2007; 29 Suppl():2547-61. PubMed ID: 18164921
[TBL] [Abstract][Full Text] [Related]
40. The genetic contribution of HLA-DRB5*01:01 to systemic lupus erythematosus in Thailand.
Louthrenoo W; Kasitanon N; Wichainun R; Wangkaew S; Sukitawut W; Ohnogi Y; Hong GH; Kuwata S; Takeuchi F
Int J Immunogenet; 2013 Apr; 40(2):126-30. PubMed ID: 22862923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
